Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02233036 · ClinicalTrials.gov registry record
Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease
A clinical trial of CGD, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 33
- Enrollment target
- 1
- Study location
NCT02233036: Completed study of CGD, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02233036 is a study of CGD that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 33 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02233036, a study of CGD, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: People who get chronic illnesses as children are living longer. When they turn 18, they switch from pediatric care to adult care. This can be a difficult change. Chronic Granulomatous Disease (CGD) is an inherited disease. It causes long-term, repeated infections. People with CGD are usually diagnosed when they are very young children. Researchers want to find out more about how young people with CGD handle the change to adult care. What they learn may make this easier for people with CGD in the future. Objective: \- To identify what helped or hurt young adults with CGD as they went from pediatric to adult care. Eligibility: \- Adults with CGD who were 18 24 years old between January 2011 and February 2014. Design: * Participants will already be enrolled in NIH studies. * Eligible people will get materials in the mail. They will get a letter with study information, an interview questionnaire, and an information sheet. * Researchers will call participants 1 week after the packets are sent. They will talk about the study and find out if the person wants to join. * An interview will be completed immediately or scheduled for the future. The interview will take about 45 minutes. The researcher will ask the participant about their disease. They will also ask about travel to NIH, being an outpatient or inpatient there, and legal documents. * Researchers may contact the subjects again by phone if they need more information at any point during the study.
Conditions Studied
Study Locations (1)
Maryland
- National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-03-26 |
| Est. Completion | 2017-01-10 |
What the finished NCT02233036 record still lists
NCT02233036 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 1 condition, with CGD appearing as the primary indexed condition, and to 0 interventions.
NCT02233036 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02233036 about?
NCT02233036 is a clinical study titled "Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease". Background: People who get chronic illnesses as children are living longer. When they turn 18, they switch from pediatric care to adult care. This can be a difficult change. Chronic Granulomatous Disease (CGD) is an inherited disease. It causes long-term, repeated infections. People with CGD are us...
What is the current status of trial NCT02233036?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2014-03-26. Estimated completion is 2017-01-10.
What conditions does trial NCT02233036 study?
This clinical trial studies the following conditions: CGD.
Who is sponsoring clinical trial NCT02233036?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02233036 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CGD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI